RecruitingPhase 2NCT07640893

A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease

A Multi-Dose, Randomized, Multicenter Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of SR604 Injection in Patients With Von Willebrand Disease

Sponsor

Shanghai RAAS Blood Products Co., Ltd.

Enrollment

24 participants

Start Date

Nov 26, 2025

Study Type

INTERVENTIONAL

Conditions

Von Willebrand Disease (vWD)

Summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in patients with von Willebrand disease.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SR604 for people with von willebrand disease (vwd). The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSR604

SR604 will be administered as SC injection.

Locations(9)

Xiangya Hospital of Central South University

Changsha, China

The First Affiliated Hospital of University of Science and Technology of China

Hefei, China

Jinan Central Hospital

Jinan, China

The First Affiliated Hospital of Guangxi Medical University

Nanning, China

The First Affiliated Hospital of Soochow University

Suzhou, China

The Second Hospital of Shanxi Medical University

Taiyuan, China

North China University of Science and Technology Affiliated Hospital

Tangshan, China

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

Tianjin, China

Henan Provincial People's Hospital

Zhengzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07640893

Related Trials

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

NCT0675485225 locations

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

NCT0558299321 locations

Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Disease

NCT0665125517 locations

A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

NCT0661020117 locations

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

NCT0711500414 locations